Lukas Hainz

Lukas Hainz

Biopharma Innovation Specialist
Lukas Hainz specializes in biopharmaceutical research and development. He unpacks research from clinical trials and explores regulatory affairs implications on the pharmaceutical industry, focusing on innovative therapies and patent development.
Machine Learning Predicts Spinal Injury Outcomes via Blood Tests
Tech & Innovation Machine Learning Predicts Spinal Injury Outcomes via Blood Tests

Imagine a world where a routine blood test, combined with cutting-edge technology, could reveal the future trajectory of a spinal cord injury (SCI) within mere days of a patient arriving at a hospital, transforming uncertainty into actionable insight. This isn’t a distant dream but the reality of a

Pharma's Direct-to-Patient Shift: A Strategic Imperative
Research & Development Pharma's Direct-to-Patient Shift: A Strategic Imperative

The pharmaceutical industry stands at a critical juncture, navigating a seismic shift from conventional distribution channels to direct-to-patient (DTP) models that promise to reshape how medications reach those in need. Once viewed as a tentative experiment to bypass intermediaries, DTP has

Absci Harnesses AI to Transform Drug Discovery in Biotech
Research & Development Absci Harnesses AI to Transform Drug Discovery in Biotech

In a world where the race to develop life-changing therapies is accelerating at an unprecedented pace, biotech innovators are turning to artificial intelligence to redefine the boundaries of drug discovery, and Absci Corporation, a Seattle-based company listed on NASDAQ under the ticker ABSI,

What Are the Latest Breakthroughs in Cancer Treatment?
Research & Development What Are the Latest Breakthroughs in Cancer Treatment?

In a world where cancer continues to challenge medical science, recent advancements offer a glimmer of hope for millions of patients grappling with this complex disease, and each year, countless individuals face diagnoses that turn their lives upside down. The urgency to develop effective,

How Is Alnylam Advancing Precision Medicine with Genomic Data?
Research & Development How Is Alnylam Advancing Precision Medicine with Genomic Data?

Imagine a world where treatments for complex diseases are tailored to an individual’s unique genetic makeup, offering hope to patients who have long been out of options, and Alnylam Pharmaceuticals, a pioneer in RNA interference (RNAi) therapeutics, is turning this vision into reality by joining

Peter Favreau’s Journey: Soft Skills in Biomedical Imaging
Tech & Innovation Peter Favreau’s Journey: Soft Skills in Biomedical Imaging

In the rapidly evolving field of biomedical imaging, where cutting-edge technology meets the urgent demands of medical research, success often hinges on more than just technical expertise. Consider the challenge faced by many scientists transitioning from academic labs to industry roles: how does

How Do Evening Meals Affect Morning Glucose in Prediabetes?
Tech & Innovation How Do Evening Meals Affect Morning Glucose in Prediabetes?

What if the secret to managing blood sugar levels tomorrow morning lies in the choices made at tonight’s dinner table? For millions grappling with prediabetes, a condition marked by elevated glucose levels not yet at diabetic thresholds, this question is more than a thought experiment—it’s a

Who Is Cedars-Sinai’s First Chief Genomics Officer?
Tech & Innovation Who Is Cedars-Sinai’s First Chief Genomics Officer?

In an era where healthcare is increasingly driven by personalized solutions, the announcement of a pioneering role at a major medical institution captures attention as a sign of transformative progress in the field of medicine. Genomic medicine, which tailors treatments to an individual’s genetic

Can Genetic Tests Predict Weight-Loss Drug Success?
Tech & Innovation Can Genetic Tests Predict Weight-Loss Drug Success?

What if a simple blood test could reveal the exact weight-loss drug that works best for an individual, cutting through years of frustrating trial and error, and offering hope in a world where obesity affects over 650 million adults? The struggle to find effective treatment is real and deeply

Can H.R. 5239 Reduce Endometrial Cancer Disparities?
Research & Development Can H.R. 5239 Reduce Endometrial Cancer Disparities?

Endometrial cancer, the most prevalent form of uterine cancer, continues to pose a significant public health challenge, particularly due to its disproportionate impact on certain demographic groups, with a growing incidence among postmenopausal women aged 55 to 64. This disease reveals stark

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later